Oruka Therapeutics Inc., a clinical-stage biotechnology company, announced its financial results for the first quarter of 2025, highlighting a strong cash position and providing updates on its research programs. As of March 31, 2025, Oruka reported cash, cash equivalents, and marketable securities totaling $373.0 million, sufficient to fund operations through 2027. The company recorded a net loss of $21.0 million for the quarter, an increase from a net loss of $7.1 million during the period from February 6, 2024, to March 31, 2024. This loss includes non-cash stock-based compensation of $4.9 million, up from $0.1 million in the same period of the previous year. Other income for the first quarter of 2025 was $4.1 million, primarily from interest earned on investments in marketable securities. Operational updates include the completion of Phase 1 trial dosing for ORKA-001, with data expected in the third quarter of 2025 and the initiation of Phase 2a trials in the second half of 2025. ORKA-002's Phase 1 initiation has been accelerated to the second quarter of 2025, with initial pharmacokinetic data anticipated by year-end 2025. The company also continues to develop ORKA-003 through preclinical stages but will not disclose further details in the first half of 2025 due to competitive considerations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.